Skip to main content
. 2022 Apr 29;28(13):2890–2897. doi: 10.1158/1078-0432.CCR-21-4520

Figure 2.

Figure 2. Key secondary efficacy endpoints. A, Relative change in unstimulated whole saliva flow rate from baseline in percent. B, Relative change in stimulated whole saliva flow rate from baseline in percent. C, Change in Xerostomia Questionnaire (XQ) summary score from baseline.

Key secondary efficacy endpoints. A, Relative change in unstimulated whole saliva flow rate from baseline in percent. B, Relative change in stimulated whole saliva flow rate from baseline in percent. C, Change in Xerostomia Questionnaire (XQ) summary score from baseline.